JPWO2020252472A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2020252472A5
JPWO2020252472A5 JP2021573759A JP2021573759A JPWO2020252472A5 JP WO2020252472 A5 JPWO2020252472 A5 JP WO2020252472A5 JP 2021573759 A JP2021573759 A JP 2021573759A JP 2021573759 A JP2021573759 A JP 2021573759A JP WO2020252472 A5 JPWO2020252472 A5 JP WO2020252472A5
Authority
JP
Japan
Prior art keywords
muc1
antibody
cell
car
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021573759A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022538778A (ja
JP7742311B2 (ja
JP2022538778A5 (https=
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/037783 external-priority patent/WO2020252472A2/en
Publication of JP2022538778A publication Critical patent/JP2022538778A/ja
Publication of JP2022538778A5 publication Critical patent/JP2022538778A5/ja
Publication of JPWO2020252472A5 publication Critical patent/JPWO2020252472A5/ja
Application granted granted Critical
Publication of JP7742311B2 publication Critical patent/JP7742311B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

JP2021573759A 2019-06-14 2020-06-15 Muc1に対する抗体およびその使用方法 Active JP7742311B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962861619P 2019-06-14 2019-06-14
US62/861,619 2019-06-14
PCT/US2020/037783 WO2020252472A2 (en) 2019-06-14 2020-06-15 Antibodies against muc1 and methods of use thereof

Publications (4)

Publication Number Publication Date
JP2022538778A JP2022538778A (ja) 2022-09-06
JP2022538778A5 JP2022538778A5 (https=) 2023-02-10
JPWO2020252472A5 true JPWO2020252472A5 (https=) 2023-02-10
JP7742311B2 JP7742311B2 (ja) 2025-09-19

Family

ID=73782134

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573759A Active JP7742311B2 (ja) 2019-06-14 2020-06-15 Muc1に対する抗体およびその使用方法

Country Status (6)

Country Link
US (1) US12448462B2 (https=)
EP (1) EP3983447A4 (https=)
JP (1) JP7742311B2 (https=)
AU (2) AU2020290579B2 (https=)
CA (1) CA3141926A1 (https=)
WO (1) WO2020252472A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3162246A1 (en) * 2019-12-20 2021-06-24 Poseida Therapeutics, Inc. Anti-muc1 compositions and methods of use
JP2024534148A (ja) * 2021-08-27 2024-09-18 ペプトロン インコーポレイテッド 新規抗muc1抗体およびその用途
KR20250156802A (ko) * 2023-03-03 2025-11-03 비원 메디슨즈 아이 게엠베하 Muc1 및 cd16a 항체 및 사용 방법
EP4676976A1 (en) * 2023-03-03 2026-01-14 Beone Medicines I GmbH Muc1 antibodies and methods of use
AU2024318998A1 (en) * 2023-07-31 2026-01-22 Sun Pharma Advanced Research Company Limited Humanized muc1 antibody and antibody drug conjugate

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
DE3788058T2 (de) 1986-08-28 1994-04-21 Teijin Ltd Zelltoxischer antikörperkomplex und verfahren zu seiner herstellung.
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5202238A (en) 1987-10-27 1993-04-13 Oncogen Production of chimeric antibodies by homologous recombination
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
JPH0494693A (ja) 1990-08-08 1992-03-26 Nippon Mektron Ltd アフィジコリンの製造法
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
EP0586505A1 (en) 1991-05-14 1994-03-16 Repligen Corporation Heteroconjugate antibodies for treatment of hiv infection
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
WO1995022618A1 (en) 1994-02-22 1995-08-24 Dana-Farber Cancer Institute Nucleic acid delivery system, method of synthesis and uses thereof
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US20020029391A1 (en) 1998-04-15 2002-03-07 Claude Geoffrey Davis Epitope-driven human antibody production and gene expression profiling
CN1871259A (zh) 2003-08-22 2006-11-29 比奥根艾迪克Ma公司 具有改变的效应物功能的经改进的抗体和制备它的方法
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
EP1815021A2 (en) 2004-11-03 2007-08-08 Almac Diagnostics Limited Transcriptome microarray technology and methods of using the same
AU2006321553B2 (en) 2005-12-08 2012-03-08 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to O8E
US8962806B2 (en) 2007-12-28 2015-02-24 Dana-Farber Cancer Institute, Inc. Humanized monoclonal antibodies and methods of use
DK2356270T3 (da) 2008-11-07 2016-12-12 Fabrus Llc Kombinatoriske antistofbiblioteker og anvendelser deraf
WO2013026015A1 (en) 2011-08-18 2013-02-21 Dana-Farber Cancer Institute, Inc. Muc1 ligand traps for use in treating cancers
AU2013256010B2 (en) 2012-05-04 2018-01-04 Dana-Farber Cancer Institute, Inc. Affinity matured anti-CCR4 humanized monoclonal antibodies and methods of use
PT2961831T (pt) 2013-02-26 2020-10-12 Memorial Sloan Kettering Cancer Center Composições e métodos para imunoterapêutica
US10059775B2 (en) * 2014-01-29 2018-08-28 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
JP6795505B2 (ja) 2014-10-06 2020-12-02 デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド ヒト化ccケモカイン受容体4(ccr4)抗体およびその使用法
EP3227324A4 (en) * 2014-12-05 2018-08-29 Memorial Sloan Kettering Cancer Center Antibodies targeting g-protein coupled receptor and methods of use
BR112017013176A2 (en) 2014-12-19 2018-05-15 Dana-Farber Cancer Institute Inc. chimeric antigen receptors and methods for using them
EP3288977B1 (en) 2015-05-01 2021-11-17 Dana-Farber Cancer Institute, Inc. Methods of mediating cytokine expression with anti ccr4 antibodies
US10617773B2 (en) * 2016-08-05 2020-04-14 Dana-Farber Cancer Institute, Inc. Antibodies against the MUC1-C/extracellular domain (MUC1-C/ECD)
WO2018174544A2 (ko) 2017-03-21 2018-09-27 주식회사 펩트론 Muc1에 특이적으로 결합하는 항체 및 그의 용도
IL269488B2 (en) * 2017-03-21 2023-09-01 Peptron Inc Conjugation of an antibody specifically for muc1 and its use
AU2019235900B2 (en) 2018-03-14 2025-12-11 Dana-Farber Cancer Institute, Inc. Engineered cells, T cell immune modulating antibodies and methods for using the same

Similar Documents

Publication Publication Date Title
JP2024510098A (ja) 抗GPRC5DxBCMAxCD3三重特異性抗体およびその使用
CA3199830A1 (en) Tumor-specific claudin 18.2 antibody-drug conjugates
TW201927824A (zh) 三鏈抗體、其製備方法及其用途
WO2020244526A1 (zh) 一种抗ceacam5的单克隆抗体及其制备方法和用途
JP2008541714A (ja) 抗cd16結合分子
JP2024508672A (ja) 新規抗cd24抗体
CN116940598A (zh) 用于治疗表达cldn18.2的实体瘤的cldn18.2/cd3双特异性抗体
US20220064254A1 (en) Anti-hk2 chimeric antigen receptor (car)
CN119233993A (zh) 用于靶向t细胞活化的cd28双特异性抗体
CN115943161A (zh) 结合mait和肿瘤细胞两者的多特异性抗体
WO2016192613A1 (zh) 具有融合至常规Fab片段的单域抗原结合片段的二价抗体
WO2022121928A1 (zh) 抗egfr的纳米抗体及其用途
CN106831995A (zh) 新型双特异性抗体及其用途
JP2024028890A (ja) メディトープ対応t細胞
JP7078237B1 (ja) 抗tspan8-抗cd3二重特異性抗体及び抗tspan8抗体
CN118510810A (zh) 一种抗体及其用途
JP2021501575A (ja) 二重特異性抗体並びにその製造方法及び使用方法
US11773172B2 (en) Anti-EGFR antibody polypeptide
CN112236456B (zh) 新型双特异性pd-1/lag-3抗体分子
JP6940732B2 (ja) がん細胞特異的抗ポドカリキシン抗体とその製造方法
CN116789836B (zh) 针对dll3的抗体及其用途
TW202233679A (zh) 選擇性地與cldn6和cd3結合的多肽構建體
CN111448214B (zh) 抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用
JPWO2020252472A5 (https=)
CN118515777A (zh) 双价或多价抗体的构建体、其建立方法及应用